Use of a sodium heparin gel in the rehabilitation of patients after cosmetic procedures

A water-soluble anticoagulant obtained about a century ago from animal tissues, heparin has since been used in the clinic for the prevention and treatment of thrombosis, including after surgical treatment, in cardiovascular and viral diseases. The main anticoagulant effect of heparin is best studied, it is based on a combined mechanism of interaction between an inhibitor of plasma serine proteinases, antithrombin and thrombin or factor Xa. According to its chemical structure, heparin is a heterogeneous, linear, highly sulfated anionic glycosaminoglycan with a wide range of relative molecular weight and charge density; these structural properties allow heparin to selectively interact with several proteins, which ensures its various pharmacological functions. Currently, 250 different proteins are known that bind to heparin and whose biological properties can be regulated by it. With the development of various directions in medicine, various properties of heparin have been revealed, which potentially have therapeutic value in other conditions with an inflammatory component. Heparin has a number of additional pharmacological activities, including antiviral, antitumor, anti-inflammatory, antihypolipidemic and antiangiogenic, which allows to expand the scope of its application. In particular, in dermatology and cosmetology, heparin has proven itself in the treatment of localized infiltrates, edema and subcutaneous hematomas. Various invasive and non-invasive procedures in cosmetology, especially in patients with undifferentiated connective tissue dysplasia, may be accompanied by edema, redness, and hematoma formation. Due to its anticoagulant, regenerative, decongestant, and anti-inflammatory properties, sodium heparin gel can shorten the rehabilitation period.

1. Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol. 2020;319(2):L211–L217. https://doi.org/10.1152/ajplung.00199.2020.

2. Chen D. Heparin beyond anti-coagulation. Curr Res Transl Med. 2021;69(4):103300. https://doi.org/10.1016/j.retram.2021.103300.

3. Wang P, Chi L, Zhang Z, Zhao H, Zhang F, Linhardt RJ. Heparin: An old drug for new clinical applications. Carbohydr Polym. 2022;295:119818. https://doi.org/10.1016/j.carbpol.2022.119818.

4. Qiu Q, Li GJ, Tang L, Guo Y, Wen LZ, Wang B et al. The efficacy of low molecular weight heparin in severe acute pancreatitis: A systematic review and meta-analysis of randomized controlled trials. J Dig Dis. 2019;20(10):512–522. https://doi.org/10.1111/1751-2980.12815.

5. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437–444. https://doi.org/10.1160/TH16-08-0620.

6. Mazilu L, Katsiki N, Nikolouzakis TK, Aslanidis MI. Lazopoulos G. Kouretas D et al. Thrombosis and Haemostasis challenges in COVID-19 – Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review. Food Chem Toxicol. 2021;148:111974. https://doi.org/10.1016/j.fct.2021.111974.

7. Abbadi A, Loftis J, Wang A, Yu M, Wang Y, Shakya S et al. Heparin inhibits proinflammatory and promotes anti-inflammatory macrophage polarization under hyperglycemic stress. J Biol Chem. 2020;295(15):4849–4857. https://doi.org/10.1074/jbc.RA119.012419.

8. Koster A, Sänger S, Hansen R, Sodian R, Mertzlufft F, Harke C et al. Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. ASAIO J. 2000;46(3): 319–322. Available at: https://journals.lww.com/asaiojournal/abstract/2000/05000/prevalence_and_persistence_of_heparin_platelet.15.aspx9.

9. Li X, Li L, Shi Y, Yu S, Ma X. Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharidestimulated human endothelial cells. J Inflamm. 2020;17:5. https://doi.org/10.1186/s12950-020-0238-7.

10. Baytas SN, Varghese SS, Jin W, Yu Y, He P, Douaisi M et al. Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin. J Med Chem. 2021;64(4):2242–2253. https://doi.org/10.1021/acs.jmedchem.0c02019.

11. Sultana R, Kamihira M. Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy. Pharmaceuticals. 2024;17(10):1362. https://doi.org/10.3390/ph17101362

12. Seffer MT, Cottam D, Forni LG, Kielstein JT. Heparin 2.0: A New Approach to the Infection Crisis. Blood Purif. 2021;50(1):28–34. https://doi.org/10.1159/000508647.

13. Zang L, Zhu H, Wang K, Liu Y, Yu F, Zhao W. Not Just Anticoagulation-New and Old Applications of Heparin. Molecules. 2022;27(20):6968. https://doi.org/10.3390/molecules27206968.

14. Walenga JM. Heparin: Much more than anti-IIa/anti-Xa. J Med Vasc. 2020;45(3):103–104. https://doi.org/10.1016/j.jdmv.2020.03.004.

15. Shlapakova PS, Dobrynina LA, Kalashnikova LA, Gubanova MV, Danilova MS, Gnedovskaya EV et al. Peripheral Blood Gene Expression Profiling Reveals Molecular Pathways Associated with Cervical Artery Dissection. Int J Mol Sci. 2024;25(10):5205. https://doi.org/10.3390/ijms25105205.

16. Svechnikova EV, Morzhanaeva MA, Gorskaya AA, Maximova YV. Protocols on correction of signs of undifferentiated connective tissue dysplasia using hardware and injection techniques in cosmetic patients. Meditsinskiy Sovet. 2023;17(2):15–25. (In Russ.) https://doi.org/10.21518/ms2023-031.

17. Cabral WA, Fratzl-Zelman N, Weis M, Perosky JE, Alimasa A, Harris R et al. Substitution of murine type I collagen A1 3-hydroxylation site alters matrix structure but does not recapitulate osteogenesis imperfecta bone dysplasia. Matrix Biol. 2020;90:20–39. https://doi.org/10.1016/j.matbio.2020.02.003.

18. Martynov AI, Nechaeva GI, Akatova EV, Vershinina MV, Viktorova IA, Gromova OA et al. Clinical recommendations of the Russian Scientific Medical Society of Internists on the diagnosis, treatment and rehabilitation of patients with connective tissue dysplasia (first revision). Medical News of North Caucasus. 2018;13(1.2):137–209. (In Russ.) https://doi.org/10.14300/mnnc.2018.13037.

19. Del Zotto E, Grassi M, Zedde M, Zini A, Bersano A, Gandolfo C et al. Risk Profile of Patients with Spontaneous Cervical Artery Dissection. Ann Neurol. 2023;94(3):585–595. https://doi.org/10.1002/ana.26717.

20. Daghlas I, Sargurupremraj M, Danning R, Gormley P, Malik R, Amouyel P et al. Migraine, Stroke, and Cervical Arterial Dissection: Shared Genetics for a Triad of Brain Disorders With Vascular Involvement. Neurol Genet. 2022;8(1):e653. https://doi.org/10.1212/NXG.0000000000000653.